Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Vaccine dealmaking
2.1. Introduction
2.2. Cancer Vaccine partnering over the years
2.3. Most active Cancer Vaccine dealmakers
2.4. Cancer Vaccine partnering by deal type
2.5. Cancer Vaccine partnering by therapy area
2.6. Deal terms for Cancer Vaccine partnering
2.6.1 Cancer Vaccine partnering headline values
2.6.2 Cancer Vaccine deal upfront payments
2.6.3 Cancer Vaccine deal milestone payments
2.6.4 Cancer Vaccine royalty rates

Chapter 3 - Leading Cancer Vaccine deals
3.1. Introduction
3.2. Top Cancer Vaccine deals by value

Chapter 4 - Most active Cancer Vaccine dealmakers
4.1. Introduction
4.2. Most active Cancer Vaccine dealmakers
4.3. Most active Cancer Vaccine partnering company profiles

Chapter 5 - Cancer Vaccine contracts dealmaking directory
5.1. Introduction
5.2. Cancer Vaccine contracts dealmaking directory

Chapter 6 - Cancer Vaccine dealmaking by technology type
Appendices
Appendix 1 - Cancer Vaccine deals by company A-Z
Appendix 2 - Cancer Vaccine deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Cancer Vaccine deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

Appendix 4 - Cancer Vaccine deals by therapy area
Appendix 5 -Deal type definitions
Appendix 6 - Further reading on dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures
Figure 1: Cancer Vaccine partnering since 2010
Figure 2: Active Cancer Vaccine dealmaking activity since 2010
Figure 3: Cancer Vaccine partnering by deal type since 2010
Figure 4: Cancer Vaccine partnering by disease type since 2010
Figure 5: Cancer Vaccine deals with a headline value
Figure 6: Cancer Vaccine deals with an upfront value
Figure 7: Cancer Vaccine deals with a milestone value
Figure 8: Cancer Vaccine deals with a royalty rate value
Figure 9: Top Cancer Vaccine deals by value since 2010
Figure 10: Most active Cancer Vaccine dealmakers since 2010

Companies mentioned
2A, 3D Medicines, A*STAR Bioprocessing Technology Institute, Abramson Cancer Center, Accelovance, Adamis Pharmaceuticals, AdaptVac, AdnaGen, Aduro BioTech, Advanced BioScience Laboratories, Advaxis, AEterna Zentaris, Affitech, Agenus Bio, Agilent Technologies, Aldevron, Alliance for Biosecurity, Alnylam Pharmaceuticals, Alpine Immune Sciences, Amaran Biotechnology, Amarna Therapeutics, American Dental Association, Analytical Bio-Chemistry Laboratories, AnGes MG, Anixa Biosciences, Annias Immunotherapeutics, Antigen Express, Antitope, Apceth, Apollomics, Ariad Pharmaceuticals, Aslan Pharma, Astellas Pharma, Asterias Biotherapeutics, AstraZeneca, Astrimmune, Aura Biosciences, Averion, Avidea Technologies, AV Therapeutics, Batu Biologics, Bavarian Nordic, Bayer, Bayer Innovation, Baylor College, Baylor College of Medicine, Baylor Institute for Immunology Research, Baylor Research Institute, Beijing Genomics Institute (BGI), Bellicum Pharmaceuticals, Beth Israel Deaconess Medical Center, BGI, BIND Biosciences, BinnoPharm, BioAlliance Pharma, BioClones, BioElpida, Biomedical Primate Research Centre, BioNTech, Biooutsource, BioSante Pharmaceuticals, Biotech Synergy, Biothera Pharmaceuticals, BioVaxys, BioVest, Bluebird Bio, Boehringer Ingelheim, Bonnie J. Addario Lung Cancer Foundation, BostonGene, Bpifrance, Bristol-Myers Squibb, Broad Institute, Broadvector, Brown University, Button Capital, Caladrius Biosciences, California Institute of Technology, Cancer Immunotherapy Trials Network, Cancer Prevention and Research Institute of Texas, Cancer Research Institute, Cancer Research Technology, Cancer Research UK, Cancer Research Wales, Cardiff University, CaroGen, Catalan Institute of Nanotechnology (ICN), Catherex, Celldex Therapeutics, Cellular Biomedicine, Center for Biomarker Research in Medicine, Centogene, ChemRar High-Tech Center, Chugai Pharmaceutical, CiMaas, City of Hope Comprehensive Cancer Center, Cleveland BioLabs, Cleveland Clinic, Clinigen, Clinipace Worldwide, Cobra Biologics, Cofactor Genomics, CoImmune, Colby Pharmaceuticals, Cristal Therapeutics, CSIRO, CureLab Oncology, CureVac, Cyplasin Biomedical, CYTLIMIC, Daiichi Sankyo, Dalton Pharma Services, Dana-Farber Cancer Institute, DanDrit Biotech, Danish Innovation Fund, Davospharma, DCPrime, Delta-Vir, Dendreon, Department of Defense, Diosynth, DNAtrix, DxS, Elicio Therapeutics, Eli Lilly, EMD Serono, Emory University, Enara Bio, Epimmune, EpiThany, Ervaxx, eTheRNA immunotherapies, Etubics, Eureka Eurostars, European Union, Evvivax, Exiqon, ExpreS2ion Biotechnologies, Federal Ministry of Education and Research (BMBF), Flaskworks, Flow Pharma, Formatech, Forska and Vax, Fraunhofer Institute for Cell Therapy and Immunology, Fred Hutchinson Cancer Research Center, G-Con, Galena Biopharma, Genentech, Generex Biotechnology, Genetic Immunity, Genexine, Genocea Biosciences, GenoLac, Genomic Expression, GenVec, Georgetown University, Georgia Health Sciences University, GeoVax, German Cancer Research Center, GISCAD Foundation, GlaxoSmithKline, Government of Rwanda, Gritstone Bio, Hanmi Pharmaceutical, Harvard University, Heat Biologics, Hefei Sageland Biotechnology, Helmholtz Zentrum Munchen, HemaCare, HemispheRx Biopharma, Henry M. Jackson Foundation, Hoffmann La Roche, Hokkaido University, Hookipa Pharma, Human Vaccines Project, Iaso Therapeutics, iBio, Icahn School of Medicine at Mount Sinai, Ichor Medical Systems, IGNITE Immunotherapy, ImaginAb, Immatics Biotechnologies, Immorna, Immune Design, ImmuneRegen BioSciences, Immunicum, ImmunID Technologies, ImmunoCellular Therapeutics, Immunomic, ImmunoPhotonics, Immunovaccine, Immunovo, Innovation Norway, Inovio Pharmaceuticals, InProTher, Intensity Therapeutics, InteRNA Technologies, IOVaxis Therapeutics, IRX Therapeutics, Jaiva Technologies, Janssen Biotech, Janssen Pharmaceuticals, Jantibody Therapeutics, Japan Vaccine, Jennerex, John Hopkins University School of Medicines, John P. Hussman Foundation, Johns Hopkins University, Johnson & Johnson Innovation, JSC Binnopharm, JSC Pharmadis, Junshi Biosciences, Juvaris BioTherapeutics, KAEL-GemVax, KaliVir Immunotherapeutics, Kanyr Pharma, KellBenx, Kindred Bio, Kiromic Biopharma, Leukaemia & Lymphoma Research, LG Life Sciences, LianBio, Ligand Pharmaceuticals, Lineage Cell Therapeutics, LineaRx, LiteVax, London Genetics, Ludwig Institute for Cancer Research, Lumos Pharma, Lung Cancer Research Foundation, LUNGevity Foundation, mAbsolve, MabVax Therapeutics, Madison Vaccines, MannKind Biopharmaceuticals, Massachusetts General Hospital, Massachusetts Life Sciences Center, Mayo Clinic, McGill University, MD Anderson Cancer Center, MDimune, MDxHealth, Medac, MediGene, MedImmune, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Methodist Hospital Research Institute, Ministry of Industry and Trade of the Russian Federation, Moderna Therapeutics, Molipharma, Morphogenesis, MorphoSys, Morphotek, Mymetics, Nanobiotix, NantBioScience, NantKwest, National Cancer Institute, National Cancer Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health, National Research Council Canada, National Surgical Adjuvant Breast and Bowel Project, NEC, NEC OncoImmunity, NeoCura Bio-Medical Technology, Neon Therapeutics, Netherlands Cancer Institute, NeuClone, Neumedicines, Neuvogen, NewVac, Nexelis, Northwest Biotherapeutics, Norwegian Cancer Society, Norwegian Research Council, Nottingham City Council, NovalGen, Novartis, Novartis Animal Health, Nuance Pharma, Nykode Therapeutics, NYU Langone Medical Center, Ohio State University, Omnimmune, Omnis Pharmaceuticals, OncoImmunity, Oncology Pharma, OncoPep, OncoQR, OncoSec Medical, Oncotherapy Science, Oncothyreon, Oncovir, Ono Pharmaceutical, OSE Pharma (Orphan Synergy Europe Pharma), Oxford BioMedica, Oxford Immunotec, Panacea Pharmaceuticals, Panacela Labs, PDC*line Pharma, Pepscan, Pfenex, Pfizer, PharmaCell, Pharmanet/i3, PharmaNet Development Group, PharmaPraxis, PhotonPharma, PlantForm, PPD, Predictive Oncology, PRIMA BioMed, Profectus Biosciences, Progenitor Cell Therapy, Prometheus Laboratories, Prostate Cancer Foundation (PCF), Provecs Medical, PsiOxus Therapeutics, Pulmotec, PX Biosolutions, Qiagen, Radboud University Nijmegen Medical Centre, Radiation Control Technologies, Radient Pharmaceuticals, RareCyte, Regen BioPharma, Regeneron Pharmaceuticals, Research Institute of the Hospital Universitari Vall d'Hebron, Riyadh Pharma, Roche, Rosetta Genomics, RXi Pharmaceuticals, Saint-Gobain Life Sciences, San Martino Hospital, Sanofi, Scancell, Selecta Biosciences, Selexis, Sellas Clinicals Holding, Seres Therapeutics, Serum Institute of India, SFJ Pharmaceuticals, Shenzhen BioScien Pharmaceuticals, SillaJen, Sirion Biotech, Skolkovo Foundation, SOTIO, Spectrum Pharmaceuticals, Spotlight Innovation, SRI International, Stanford University, Stellar Biotechnologies, Stellar Pharmaceuticals, Stemline Therapeutics, Sumitomo Dainippon Pharma, Susan G. Komen for the Cure, Takis Biotech, TapImmune, Targovax, Tasly Pharmaceuticals, Telormedix, Terumo Blood and Cell Technologies, Teva Pharmaceutical Industries, The International AIDS Vaccine Initiative, The Parker Institute For Cancer Immunotherapy, Theravectys, The Regents of the University of California, Thomas Jefferson University, ToleRx, Torigen Pharmaceuticals, Torrey Pines Institute for Molecular Studies, Trans-Hit Bio, Transgene, Transgene Tasly Biopharmaceutical, Transgenomic, Treos Bio, TYG Oncology, UbiVac, UK Government, University Medical Center Groningen, University of Alabama at Birmingham, University of Basel, University of California, Davis, University of California, San Diego, University of California Berkeley, University of Chicago, University of Connecticut, University of Copenhagen, University of Greifswald, University of Helsinki, University of Massachusetts Medical School, University of Miami, University of North Carolina, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, University of Queensland, University of Rostock, University of Rouen, University of South Florida, University of Texas at El Paso, University of Turin, University of Western Ontario, Vaccibody, Vaccine and Gene Therapy Institute of Florida (VGTI-FL), Vaccinogen, Valo Therapeutics, Vanderbilt University, Vaxeal, Vaxil BioTherapeutics, Vaximm, VBI Vaccines, Vedantra Pharmaceuticals, VGX International, Victor Medical, Vinnova, Viome, ViroMed, Vivalis, VLP Therapeutics, VLST Corporation, Voltron Therapeutics, VU University Amsterdam, Vyriad, Washington University in St Louis, Weill Cornell Medical College, Western Oncolytics, Wilex, Wistar Institute, WuXi Biologics, Wyss Institute, Xencor, Y-Biologics, Y-mAbs Therapeutics, Yale University, Yamaguchi University